This clinical-stage biotech company utilizes plant-based production systems to generate plant-derived proteins, vaccines, and therapeutic materials. By replacing traditional bioreactor fermentation methods, the company enables clients to accelerate product development and lower production costs.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of producing proteins, vaccines, and therapeutic materials often rely on bioreactor fermentation, which can be slow, expensive, and difficult to scale. This can hinder the development and accessibility of critical biopharmaceuticals, particularly in regions with limited infrastructure.
Solution
Baiya Phytopharm leverages a plant-based production system, called BaiyaPharming™, to produce plant-derived proteins, vaccines, and therapeutic materials. This platform offers a faster and more cost-effective alternative to traditional bioreactor fermentation, accelerating product development and reducing manufacturing expenses. The company's technology enables the rapid production of biopharmaceutical products, including monoclonal antibodies and vaccines, addressing unmet medical needs. Baiya Phytopharm operates through three divisions: MP Solution, offering contract manufacturing, development, and testing services; and BGF Plantrix, focused on growth factors and cytokines for various industries, including cosmetics. The company's pipeline includes candidates for cancer, infectious diseases, and neglected tropical diseases.
Target Audience
The primary target audience includes biopharmaceutical companies seeking faster and more cost-effective production methods, as well as researchers and clinicians focused on developing therapeutics and vaccines for unmet medical needs.
Features
- BaiyaPharming™ platform for rapid and scalable production of biopharmaceuticals
- cGMP-compliant manufacturing facility for clinical material production
- Plug 'n' Play strategy across PlantamAb™ (plant-derived antibodies), Fuseplanta™ (antibody fusion proteins), and Multiplanta™ (multispecific antibodies) R&D initiatives
- MP Solution: Contract manufacturing, development, and testing services adhering to regulatory guidelines
- BGF Plantrix: Production of growth factors and cytokines for alternative meats, cosmetic raw materials, and support materials for gene and cell therapy
- Development of multifunctional antibody derivatives applicable in immune-oncology and infectious diseases